# Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.

> **NCT05472324** · PHASE2 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 205 (actual)

## Conditions studied

- Severe Asthma

## Interventions

- **DRUG:** TQC2731 injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05472324
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-23
- **Primary completion:** 2025-03-05
- **Final completion:** 2025-03-05
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05472324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05472324, "Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05472324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*